Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents

Abstract

Type 2 diabetes (T2D) occurs when there is insufficient insulin release to control blood glucose, due to insulin resistance and impaired β-cell function. The GPR39 receptor is expressed in metabolic tissues including pancreatic β-cells and has been proposed as a T2D target. Specifically, GPR39 agonists might improve β-cell function leading to more adequate and sustained insulin release and glucose control. The present study aimed to test the hypothesis that GPR39 agonism would improve glucose stimulated insulin secretion in vivo. A high throughput screen, followed by a medicinal chemistry program, identified three novel potent Zn²⁺ modulated GPR39 agonists. These agonists were evaluated in acute rodent glucose tolerance tests. The results showed a lack of glucose lowering and insulinotropic effects not only in lean mice, but also in diet-induced obese (DIO) mice and Zucker fatty rats. It is concluded that Zn²⁺ modulated GPR39 agonists do not acutely stimulate insulin release in rodents.

About the Authors:

Ola Fjellström

Contributed equally to this work with: Ola Fjellström, Niklas Larsson

* E-mail: [email protected]

Affiliation: Medicinal Chemistry CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Niklas Larsson

Contributed equally to this work with: Ola Fjellström, Niklas Larsson

Affiliation: Discovery Sciences, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Shin-ichiro Yasuda

Affiliation: Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Takuma Tsuchida

Affiliation: Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Takahiro Oguma

Affiliation: Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Anna Marley

Affiliation: Discovery Sciences, AstraZeneca R&D, Mereside, United Kingdom

Charlotte Wennberg-Huldt

Affiliation: Bioscience CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Daniel Hovdal

Affiliation: DMPK CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Hajime Fukuda

Affiliation: DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Yukimi Yoneyama

Affiliation: DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Kazuyo Sasaki

Affiliation: Pharmacology Research Laboratories II, Mitsubishi Tanabe Pharma Corporation, Kawagishi, Toda-shi, Saitama, Japan

Anders Johansson

Affiliation: Medicinal Chemistry CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Sara Lundqvist

Affiliation: Discovery Sciences, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Johan Brengdahl

Affiliation: Discovery Sciences, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Richard J. Isaacs

Affiliation: Molecular Sensing, Inc., Nashville, Tennessee, United States of America

Daniel Brown

Affiliation: Molecular Sensing, Inc., Nashville, Tennessee, United States of America

Stefan Geschwindner

Affiliation: Discovery Sciences, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Lambertus Benthem

Affiliation: Bioscience CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Claire Priest

Affiliation: Discovery Sciences, AstraZeneca R&D, Mereside, United Kingdom

Andrew Turnbull

Affiliation: CVMD iMed, AstraZeneca R&D Gothenburg, Mölndal, Sweden

Introduction

T2D occurs when the pancreatic β-cell can no longer release sufficient insulin to control blood glucose, due to insulin resistance in liver, muscle and adipose tissue. The mechanisms leading to β-cell failure remain debated. However, high levels of glucose and fatty-acids (glucolipotoxicity) activate pathways related to endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, apoptosis and islet inflammation which contribute to loss of functional β-cell mass [1]. Agents that will restore insulin secretion by counteracting these effects are therefore of interest as potential therapies for T2D. Glucose is the main physiological trigger for insulin release and this insulinotropic effect is enhanced by other factors that signal through G-protein-coupled receptors (GPCRs), a number of which are expressed in the pancreatic islet [2]. Some islet GPCRs activate the Gα_q pathway with subsequent activation of phospholipase C and others activate Gα_s, which increases intracellular cAMP, both leading to increased insulin secretion. GPCRs therefore represent promising targets for therapy in T2D, with potential to improve β-cell function.

GPR39 is a GPCR that is mainly expressed in peripheral tissues with important metabolic activity, such as pancreatic β-cells, liver, gastrointestinal tract, and adipose tissue [3–5]. Zn²⁺ has been shown to be a stimulator of GPR39 activity via the Gα_q, Gα_s and Gα_12/13 pathways and has been suggested to be an important physiological regulator of the receptor [6,7]. A number of studies into effects of GPR39 modulation suggest a role of the receptor in glucose homeost{{}}asis and particularly β-cell function. A number of these suggest an overall protective role of GPR39 activity. For example, GPR39 knock-out mice have a reduced glucose tolerance and reduced insulin release in response to glucose challenge in mice fed a variety of different diets [4,8]. Consistent with this protective effect, GPR39 overexpression in β-cells, protects against the gradual hyperglycemia observed after low-dose STZ treatment of mice [9]. However, other studies have suggested a protective role of loss of GPR39 function in rodents [10–12].

To clarify the role of endogenous GPR39 and identify the potential for pharmacological modification of GPR39 activity to modify glucose-stimulated insulin secretion and be a potential treatment for T2D, we have identified potent and selective GPR39 agonists and tested their acute insulinotropic effects in normal mice and in rodent models of T2D.

Materials and Methods

Preparation of AZ7914, AZ4237, AZ1395

6-(3-chloro-2-fluoro-benzoyl)-2-(2-methylthiazol-4-yl)-3,5,7,8-tetrahydropyrido-[4,3-d]pyrimidin-4-one (AZ7914), 6-[(4-chlorophenyl)methyl]-7-hydroxy-5-methyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (AZ4237), 3,4-bis-(2-imidazol-1-ylethoxy)-benzonitrile (AZ1395), were prepared as described in the Supporting Information section (S1 File).

Cloning of GPR39 and cell culture

Full length human (AF034633), rat (DM091294) and mouse (BC085285) GPR39 (GeneArt–Life Technologies, Carlsbad, CA) were subcloned into the pIRESneo3 vector (Clontech, Mountain View, CA). The resulting expression vectors hGPR39-, rGPR39- and mGPR39-pIRESneo3 were transfected into HEK293s cells (ATCC CRL-1573) using Lipofectamine 2000 (Life Technologies). Individual clones were isolated using flow cytometry with a FACSVantage SE DIVA (Becton Dickinson, Franklin Lakes, NJ) and clones were chosen based on responses to Zn²⁺ measured in a cAMP assay (see below). Similar to results by Holst et al. [7,13], clones expressing GPR39 displayed constitutive activity in inositol phosphate assays (up to 30% of maximal Zn²⁺ stimulated activity) but not in cAMP assays. HEK293s-derived cell lines were cultured at 37°C, 10% CO₂ and 95% humidity in DMEM supplemented with 10% FBS and 600 μg/ml Geneticin (Life Technologies). The mouse pancreas epithelial cell line NIT-1 (ATCC CRL-2055) with endogenous expression of GPR39 was cultured at 37°C, 5% CO₂, and 95% humidity in Ham´s F12 (Life Technologies) supplemented with 10% FBS.

cAMP assay

Measurements of cAMP production were performed using homogeneous time resolved fluorescence (HTRF) cAMP dynamic kits (CisBio, Codolet, France). All buffers and reagents were according to manufacturer’s protocol. In short, 0.1 μl of compounds in DMSO were added to small-volume 384-well plates (Greiner, Frickenhausen, Germany). 12,000 (5 μl) cells in Hank’s balanced salt solution (HBSS) (Life Technologies) and 20 mM HEPES (pH7.4; Life Technologies) were added per well. The production of cAMP was stimulated for 75 min at 37°C by addition of 5 μl 3-isobutyl-1-methylxanthine (0.375 mM final concentration; Sigma-Aldrich, St Louis, MO) and ZnCl₂ (0 to 30 μM; Sigma). The reaction was stopped by addition of 5 μl cAMP-d2 and 5 μl anti-cAMP cryptate. The cAMP production was detected by HTRF (λ_ex = 340 nm, λ_em = 665 and 615 nm) using a Pherastar (BMG Labtech, Ortenberg, Germany).

IP₁ assay

IP₁ assays were performed using IP-One Tb kits (CisBio). IP₁ production was detected by HTRF as described above. Buffers and reagents were according to manufacturers’ protocols except LiCl concentrations in stimulation buffer which were 50 mM in assays employing HEK293s-hGPR39 cells and 20 mM in assays using NIT-1 cells. For assays using HEK293s-hGPR39 cells, 12,500 cells per well were dispensed into small-volume 384-well plates (Greiner) and IP₁ production was stimulated in the presence of compounds for 30 min at 37 ˚C in a total volume of 20 μl. For assays using NIT-1 cells, 25,000 cells per well were seeded into poly-D-lysine coated 384-well plates (Becton-Dickinson) and cultured in Ham´s F12 medium with 10% FBS. After 48 h, cells were washed with stimulation buffer and IP₁ production stimulated in the presence of compounds for 45 min at 37 ˚C in a total volume of 60 μl.

Dynamic mass redistribution (DMR)–label-free assay

DMR assays were performed using an Epic instrument (Corning Inc., Corning, NY). 12,000 cells per well were cultured for 24 h in 384-well fibronectin-coated Epic biosensor plates (Corning). On the day of experiment, culture medium was removed and replaced with 30 μl buffer A (HBSS, HEPES 20 mM pH7.4, 1% DMSO, 0.01% BSA) using an EL406 (Bio-Tek). Plates were incubated at 26 ˚C for 1 h inside the Epic to allow for temperature equilibration. A baseline was read for 2 min, and then 15 μl compounds in buffer A were added using a CyBi-Well vario (CyBio) and DMR was detected during 45 min.

Back-scattering interferometry (BSI) binding assay

Membranes (1.3 mg protein/ml) from HEK293s-hGPR39 and untransfected HEK293s cells were diluted 11-fold in 50 mM Tris, pH 7.5, 5 μM ZnCl2, 0.3% DMSO. The compounds were diluted from 10 mM in DMSO to the final maximum stock concentration of 30 μM with 50 mM Tris, pH 7.5, 5 μM ZnCl2, 24.6 mM sucrose. A 3-fold serial dilution was performed with the compounds and refractive index-matched assay buffer, 50 mM Tris, pH 7.5, 5 μM ZnCl2, 24.6 mM sucrose, 0.3% DMSO. The compound serial dilutions were mixed 1:1 with either the GPR39 or wild type membrane fractions in a 96-well polypropylene microplate (Eppendorf, Hauppauge, NY). After a 2 hour incubation at room temperature, the plate was analyzed on a pre-commercial prototype BSI instrument (Molecular Sensing, Inc., Nashville, TN) [14]. Binding signal was expressed as the phase shift in the interference fringe patterns on a CMOS camera as measured in milliradians. The data from the wild type membrane fractions was subtracted from the GPR39-expressing fractions point by point to obtain the specific binding interaction of the compounds with GPR39 and fit to one-site binding or two-site binding models using built-in models in Graphpad Prism to determine K_D values for each compound.

Isothermal calorimetry (ITC)

To determine the binding affinities of the discussed compounds for Zn²⁺, isothermal titration calorimetry experiments were conducted on a MicroCal ITC-200 system (Malvern Instruments) at a temperature of 30°C. The compounds, provided as a DMSO stock solution of 10 mM, were diluted in 50 mM HEPES (pH 7.4) and 150 mM NaCl to reach a final nominal concentration of 400 μM (= 4% (v/v) final DMSO concentration). Complete titration of the compounds was typically achieved by injecting 27 x 1.3 μl aliquots of 5 mM ZnCl₂ provided in a matching buffer. The thermodynamic binding parameters were extracted by non-linear regression analysis of the binding isotherms (Microcal Origin version 7.0 software package). A single site binding model was applied, yielding binding enthalpy (ΔH), stoichiometry (n), entropy (ΔS), and association constant (K_a). All experiments have been performed in triplicate to allow for error estimations.

Calculations and statistical analysis

Concentration response data were fitted with a four parameter logistic fit using Eq 1,(1)where A is no activation, B is full activation, C is the EC₅₀ and D is the Hill slope.

To facilitate visualization of data, efficacy was normalized to % effect of the maximum response stimulated by in each assay.

Concentration response curves for the interaction between ortosteric and allosteric ligands in the DNR assay were globally fitted to the operational model of allosterism and agonism as described in Leach et al. [15]. Binding data were fitted using one site or two site binding models.

Insulin secretion assays

INS-1E cells obtained from Dr. Wollheim (Univ. Geneva, Switzerland), were grown in Roswell Park Memorial Institute medium (RPMI) 1640 (Life technologies) supplemented with 5% of fetal bovine serum (Thermo Fischer Scientific, Inc. Waltham, MA). At 4 or 5 days before the assay, cells were plated in 24-well plates at 2 × 10⁵ cells /well. At the day of the assay, cells were washed twice by Krebs-Ringer bicarbonate (KRB) buffer containing 0.1% BSA (pH7.4) and pre-incubated at 37°C for 30 min. The cells were washed twice again, and the buffer was replaced by KRB buffer containing 0, 1, 3 and 10 μM of compounds and 11.1 mM of glucose. In order to examine whether Zn²⁺ has an enhancing effect on the activity of each compound, 20 μM of Zn²⁺ was added in the incubation buffer as necessary. After cells were stimulated at 37°C for 1 h, the reaction was terminated by placing on ice. The buffer was collected from each well and precipitated (1000 rpm for 2 min at 25°C) in order to be separated from the cells. For each sample, concentration of insulin was measured using HTRF insulin kit (Cisbio).

Insulin secretion in mouse islets

C57BL6 mice were humanely killed according to UK Home Office–approved procedures and islets were isolated as described in Johnson et al. [16]. Islets were then handpicked and cultured overnight in RPMI 1640 (5 mM glucose; Invitrogen, Paisley, Scotland, U.K.), 10% FCS (Invitrogen), and penicillin/streptomycin (100 units/ml, 0.1 mg/ml; Invitrogen) at 37°C in a 5% CO₂ humidified atmosphere. The islets were handpicked in groups of three and incubated in HEPES-balanced Krebs-Ringer phosphate (KRH) buffer, composed of 129 mM NaCl, 5 mM NaHCO₃, 4.8 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 10 mM HEPES, 2.5 mM CaCl₂, 1mM glucose, and 0.1% BSA (pH 7.4, NaOH) for 30min at 37°C and in 5% CO₂. KRH buffer containing the appropriate glucose concentration and compound was added, and the islets were incubated for 2 h at 37°C and in 5% CO₂. After incubation, the islets were centrifuged, the medium was collected, and the amount of secreted insulin was determined using HTRF assay (CisBio). Islet data points were obtained from six replicates and repeated three times.

Animals.

Six-week-old male C57BL/6J mice were purchased from CLEA (Tokyo, Japan). Fourteen-week-old and fifteen-week-old male DIO mice were purchase from Charles River Japan (Yokohama, Japan). They were used after at least one week acclimation period. C57BL/6J mice were allowed free access to a normal diet (CRF-1, Oriental Yeast, Tokyo, Japan). DIO mice were allowed free access to a high-fat diet with 60 kcal% fat (D12492, Research Diets, New Brunswick, NJ). They were kept under standard 12-h light/dark cycle. Animal experiments were approved by the Institutional Animal Care and Use Committee of Mitsubishi Tanabe Pharma Corporation.

Intraperitoneal glucose tolerance test (IPGTT) in C57BL/6J mice

Seven-week-old and eight-week-old C57BL/6J mice were used. Mice were fasted overnight and were randomly grouped. Five ml/kg of a solution of vehicle (10% dimethylformamide (DMF)/18% Cremophore) or compounds were intraperitoneally (IP) administered. Thirty min later, 1.5 g/20 ml/kg of glucose solution was IP administered. Blood samples were obtained from the tail vein at -30, 0, 15, 30, 60, and 120 min after glucose challenge. Plasma glucose was measured using Glucose CII Test Wako Kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin was measured using Ultra Sensitive Mouse Insulin ELISA Kit (Morinaga, Yokohama, Japan).

IPGTT in DIO mice

Fifteen-week-old and twenty one-week-old DIO mice were used. The mice were fasted for 3 h and were randomly grouped based on the body weight. Five ml/kg of a solution of vehicle (10% DMF/18% Cremophore) or compounds were administered IP. Thirty min later, 1.0 g/10 ml/kg of glucose solution was administered IP. Blood samples were obtained from the tail vein at -30, 0, 15, 30, 60, and 120 min after glucose challenge. Plasma glucose and insulin were measured.

Data analysis

Statistical analysis was performed using SAS9.1.3 with student’s t-test or Dunnett’s test. All data were expressed as mean ± standard error of mean (SEM). P values of <0.05 were considered to be statistically significant.

Measurement of unbound compound concentration in plasma

Plasma protein binding of test compound was examined by an equilibrium dialysis method. The compound was mixed with blank mouse plasma to a concentration of 10 μM. The plasma sample and PBS were added to a sample chamber and a buffer chamber of an equilibrium dialysis device, respectively. The device was incubated for 4 h at 37°C in a CO₂ incubator (oscillation: 180 rpm). After incubation, an aliquot in each chamber was collected. They were mixed with acetonitrile/methanol (50/50, v/v) and were centrifuged. The supernatants were analyzed by LC-MS/MS. Plasma unbound fraction (f) was calculated by Eq 2,(2)where C_f and C_t represent the compound concentration in the buffer and sample chamber, respectively.

LC-MS/MS analytical procedure for test compounds

Chromatography was performed on an Acquity UPLC system (Waters, Milford, MA) equipped with an Acquity UPLC BEH C₁₈ column (30 mm × 2.1 mm, i.d., 1.7 μm particle size, Waters) maintained at 50°C. The mobile phase consisted of 0.025% formic acid (A) and acetonitrile (B). The initial mobile phase was 98% A and 2% B, and the proportion of acetonitrile was linearly increased to 95% over 2.2 min with a flow rate of 0.5 mL/min. An autosampler was set at 8°C with an injection volume of 5 μL. MS analysis was performed on a Waters Xevo TQ-S tandem quadrupole mass spectrometer (Waters) using an electrospray source in positive ion mode. The ionization source parameters were capillary voltage 3.0 kV; source temperature 150°C; desolvation gas temperature 600°C at a flow rate of 1200 L/h; and cone gas flow rate 100 L/h. Nitrogen (99.9% purity) and argon (99.9999% purity) were used as cone and collision gases, respectively. The following selected ion monitoring transitions were used for analysis: 405.04 > 107.90 for AZ7914, 318.06 > 299.81 for AZ4237 and 324.14 > 67.84 for AZ1395, at collision energy of 28, 16 and 34, respectively. Data acquisition was performed by MassLynx Ver. 4.1 software with a QuanLynx program (Waters).

Calculation of free fraction of drug at in vitro conditions

The free fraction in the INS-1E assay, containing 0.1% w/w BSA, was calculated by using the equilibrium conditions of a single binding site model as in Eq 3.

(3)

The affinity constant, K_a, was first estimated from f_u in mouse plasma (P_tot = 470 μM) by substituting [C_u] with C_tot—[CP] and [P] with P_tot—[CP] and solving the relation for CP. The free fraction in mouse plasma corresponds to 1—CP/P_tot. The derived K_a is then used to calculate the free fraction in the in vitro conditions by using the protein concentration of the assay (~15 μM, Mw~67 kDa).

Pharmacokinetic-pharmacodynamic (PKPD) analysis

The unbound plasma concentrations were calculated by correcting the total plasma concentration derived from the LC/MS analysis by the free fraction, f_u. The exposure in terms of the area under the unbound concentration-time curve in the interval 30–60 min after drug administration AUCu_30–60min, i.e. the interval 0–30 min after glucose challenge, was calculated using the linear up-log down trapezoidal method in the non compartmental module of Phoenix 6.2 (Pharsight). The average concentration in the interval, C_u,av, was estimated from the ratio of AUCu_30-60min and the time interval. The ratio between C_u,av and the EC₅₀ of the different in vitro potency assays was calculated for each compound and dose administered.

Results

High through-put screen

Approximately 860,000 compounds from the AstraZeneca compound collection were screened in a cAMP assay run in the presence of 5 μM Zn²⁺. After retesting of actives, removal of false positives (actives in GPR39 null cell lines), and confirmation of activity in an orthogonal DMR secondary screen, about 7,000 GPR39 agonists remained. Selection criteria at this stage in the screening cascade considered mainly potency, logD and structural diversity. Representatives from 20 chemical clusters were further characterized with regard to both potency and efficacy measures as those shown in Table 1, as well as absorption, distribution, metabolism and excretion (ADME) parameters such as solubility, intrinsic clearance, CYP inhibition and Caco2 permeability. A limited medicinal chemistry program on selected clusters with a focus on GPR39 potency and ADME parameters in the mouse led to the identification of several clusters from which tool compounds could be derived. Representatives from three different clusters are shown in Fig 1, which were selected for an in depth in vitro and in vivo characterization.

[Figure omitted. See PDF.]

Fig 1. Chemical structures of four GPR39 agonists.

AZ7914, 6-(3-chloro-2-fluoro-benzoyl)-2-(2-methylthiazol-4-yl)-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one; AZ1395, 3,4-bis(2-imidazol-1-ylethoxy)benzonitrile; AZ4237, 6-[(4-chlorophenyl)methyl]-7-hydroxy-5-methyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid.

https://doi.org/10.1371/journal.pone.0145849.g001

[Figure omitted. See PDF.]

Table 1. In vitro characterization of three GPR39 agonists and Zn²⁺ in functional and binding assays.

https://doi.org/10.1371/journal.pone.0145849.t001

In vitro characterization

GPR39 couples to the Gα_q, Gα_s and Gα_12/13 pathways [3], and Zn²⁺ is its cognate ligand [6,7]. Therefore, several assays run both in the absence and presence of Zn²⁺ (in general 5 μM) were required for an appropriate profiling of the lead compounds. A summary of the results is presented in Table 1, with selected corresponding concentration response curves shown in Fig 2.

[Figure omitted. See PDF.]

Fig 2. AZ7914 (A), AZ4237 (B) and AZ1395 (C) ten point concentration response curves for in vitro screens.

Concentration responses of compounds were measured with DMR, IP₁ and cAMP assays in the absence (-) or presence of 5 μM Zn²⁺ (+) as indicated in the figure. Lines represent fits to Eq 1. Cells employed were HEK293s-hGPR39 (hGPR39), untransfected HEK293s (HEK), and NIT-1 cells endogenously expressing GPR39. Responses were normalized to AZ1395 in each assay and presented as % effect of control. For HEK293s and HEK293s-hGPR39 cells, individual DMR assays were run in singlicates and IP₁ and cAMP assays were run in triplicates. Values shown are means ± SEM of typically three (two to five) independent experiments. For NIT-1 cells, IP₁ assays were typically run in duplicates (one to four experiments), and values are shown as means with error bars representing range. EC₅₀ values calculated from the data in Fig 2 are summarized in Table 1.

https://doi.org/10.1371/journal.pone.0145849.g002

The DMR assay is agnostic of signaling pathway and is thus able to reflect one or several pathways acting simultaneously [17]. All three compounds displayed submicromolar EC₅₀ values in the presence of Zn²⁺, which were also in general similar in the corresponding rat and mouse assays. The DMR potencies in the absence of Zn²⁺ were considerably lower for all three compounds, and also indicate variable degrees of Zn²⁺ dependencies.

Zn²⁺ by itself displayed agonism in the three assays with EC₅₀ values of 12 μM (cAMP), 24 μM (IP₁) and 14 μM (DMR). Importantly, the maximum effect stimulated by Zn²⁺ alone was lower than compound-stimulated responses, approximately 60% in cAMP and IP₁ assays and 35% in DMR assays compared to the maximum response stimulated by AZ1395 together with 5 μM Zn²⁺.

The cAMP and IP₁ assays capture Gα_s and Gα_q signaling, respectively. For the compounds, EC₅₀ values were between 0.39 and 2.3 μM in the cAMP assay in the presence of Zn²⁺, and were up to 23-fold higher than the corresponding DMR values, see Table 1. In contrast, the IP₁ and DMR EC₅₀ values were more closely matched, which may suggest that the DMR signal mainly reflects Gα_q signaling.

The IP₁ assay was also performed on native mouse NIT-1 β-cells. Zn²⁺ by itself exhibited no agonistic effects in the native NIT-1 cells, despite proven GPR39 expression [8]. All three compounds in the presence of Zn²⁺ displayed potencies in the 1 μM range, and their efficacies varied between 47 and 100%, using AZ1395 as reference agonist. In the absence of Zn²⁺, the compounds were essentially inactive (EC₅₀ >33 μM), see Table 1. The enhanced compound potencies in the NIT-1 cells in the presence of Zn²⁺ is an indirect indication that the agonistic effects of the compounds are GPR39 mediated and that the modulating effects of Zn²⁺ remain.

To address if the agonists were directly interacting with GPR39 we employed binding assays based on back-scattering interferometry (BSI) (Fig 3) [14]. Compound binding affinities in the presence of 5 μM Zn²⁺ calculated using one-site binding models are presented in Table 1. BSI also allowed detection of Zn²⁺ binding to GPR39. For Zn²⁺, data fitted best to a two-site binding model with a high-affinity K_D of 0.53 ± 0.12 μM and low-affinity K_D of 211 ± 63 μM.

[Figure omitted. See PDF.]

Fig 3. AZ7914 (A), AZ4237 (B), AZ1395 (C) and Zn²⁺ (D) concentration response curves in back-scattering Interferometry binding assays.

Compounds were incubated with membranes from HEK293s-hGPR39 and HEK293s cells. AZ7914, AZ4237 and AZ1395 were incubated in the presence of 5 μM ZnCl₂. Signals from HEK293s membranes (reference curves) were subtracted from HEK293s-hGPR39 membrane signals at each concentration point to derive GPR39 specific binding (difference curves). Values shown are means ± SD of three (AZ7914, AZ4237 and AZ1395) or four (Zn²⁺) independent experiments. One-site binding models were used to calculate K_D values for AZ7914, AZ4237 and AZ1395 summarized in Table 1. For Zn²⁺, data was fitted to a two-site binding model.

https://doi.org/10.1371/journal.pone.0145849.g003

The structures of AZ7914, AZ4237 and AZ1395 suggested that they may potentially directly interact with Zn²⁺. We used isothermal titration calorimetry (ITC) to address this. All three compounds interacted with Zn²⁺ and binding parameters are summarized in Table 2.

[Figure omitted. See PDF.]

Table 2. Binding parameters for Zn²⁺-interaction with AZ1395, AZ4237 and AZ7914 determined by ITC at 30°C.

https://doi.org/10.1371/journal.pone.0145849.t002

Utilizing the DMR platform, positive allosteric modulator (PAM) experiments were performed in order to more accurately determine the influences of Zn²⁺ on the three compounds, see Fig 4. Compound dose responses were generated at 10 different Zn²⁺ concentrations, spanning 0 to 30 μM. The presence of Zn²⁺ increased potencies of compounds up to 10000-fold. Data were initially globally fitted to the operational model of allosterism and agonism described by Leach et al [15]. However, fits obtained were not of sufficient quality. We therefore decided to calculate modulation in a more simplistic way, here called PAM EC₅₀ and defined as the concentration of modulator (Zn²⁺) causing half maximum potentiation of agonist potency. PAM EC₅₀ of Zn²⁺ span the range 3.4 to 4.5 μM for the three compounds as illustrated in the inserts in Fig 4.

[Figure omitted. See PDF.]

Fig 4. Interdependencies of GPR39 agonists and Zn²⁺; AZ7914 (A), AZ4237 (B), AZ1395 (C), AZ4502 (D).

Concentration responses of compounds were measured in DMR assays in the absence or presence of fixed concentrations of Zn²⁺ as indicated in the figure. Data are presented as the raw wavelength shifts in pm caused by compound treatment. Lines represent fits to Eq 1. Compound EC₅₀ values in the presence of different Zn²⁺ concentration are shown. The experiment was run using duplicate samples and is representative of three independent experiments. Values are means of duplicates with error bars representing range. In the inserts, the obtained compound Log EC₅₀ values are plotted as a function of Zn²⁺ concentration and used to calculate the concentration of Zn²⁺ causing half maximum shift of compound EC₅₀ curves, i.e. Zn²⁺ PAM EC₅₀ values.

https://doi.org/10.1371/journal.pone.0145849.g004

The same data were analyzed as Zn²⁺ dose response curves at different fixed concentrations of compound. From this reverse analysis, the Zn²⁺ EC₅₀ values varied between 19 and 2.1 μM going from 0 to 33 μM fixed compound concentrations. The compound PAM effects, shifting Zn²⁺ EC₅₀ up to 7 fold, were moderate compared to the converse Zn²⁺ PAM effects on the AZ compounds. With respect to relative efficacies, E_max for Zn²⁺ alone was approximately 35% of E_max for Zn²⁺ together with any of the GPR39 agonists. E_max for AZ1395 in the absence of Zn²⁺ were approximately 75%. AZ7914 and AZ4237 responses in the absence of Zn²⁺ did not plateau and E_max values were therefore not calculated.

Two biological effect assays were developed to measure glucose stimulated insulin secretion (GSIS), one in rat INS-1E β-cells and one in mouse islets. Fig 5 displays the INS-1E data in the absence and presence of Zn²⁺. AZ7914, AZ4237 and AZ1395 all showed increases in GSIS in the presence of Zn²⁺. In the islet GSIS experiments none of the compounds in the presence and absence of Zn²⁺ displayed significantly increased GSIS effects at the 1 and 10 μM compound concentrations tested (Fig 6).

[Figure omitted. See PDF.]

Fig 5. Insulin secretion assays in INS-1E cells.

Effect on insulin secretion by each compound. Cells were treated with 1, 3 and 10 μM of AZ7914 (A, B), AZ4237 (C, D), AZ1395 (E, F). The assays were performed in the absence or presence of 20 μM of Zn²⁺. Values were calculated as the ratio of insulin concentration compared to the basal control and expressed as the average of three separate measurements ± SEM. *P<0.05, **P<0.01, ***P<0.001 versus control analyzed by Dunnett.

https://doi.org/10.1371/journal.pone.0145849.g005

[Figure omitted. See PDF.]

Fig 6. Insulin secretion assays in mouse islets.

Effect on insulin secretion by each compound. Islets were treated with 1 and 10 μM of AZ7914 (A), AZ4237 (B), AZ1395 (C). The assays were performed in the absence or presence of 5 μM of Zn²⁺. Values were calculated as the ratio of insulin concentration compared to the basal control and expressed as the average of three separate measurements ± SEM.

https://doi.org/10.1371/journal.pone.0145849.g006

In vivo characterization

IPGTT was chosen as the key experiment for assessing the acute in vivo utility of GPR39 agonists. First, the three compounds were tested by IP administration to fasted lean mice 30 min before IP administration of 1.5 g/kg glucose. The GLP-1 agonist exendin-4 [18] was used as positive control, in this and all presented in vivo studies. Effect data on glucose and insulin levels are shown in Fig 7. The three agonists showed neither significant glucose lowering effects nor significant insulinotropic effects.

[Figure omitted. See PDF.]

Fig 7. IPGTT in C57BL/6J mice; AZ7914 (A), AZ4237 (B), AZ1395 (C).

Compounds (black triangles: 30 mg/kg, black circles: 100 mg/kg, grey circles: exendin-4, 1 μg/kg) or vehicle (white circles) were IP administered to fasted C57BL/6J mice at -30 min. Glucose solution (1.5 g/kg) was given IP at 0 min. Values are mean ± SEM (n = 7). ^#P<0.05, ^##P<0.01, ^###P<0.001 versus vehicle (repeated measures ANOVA followed by student’s t-test).*P<0.05, **P<0.01, ***P<0.001 versus vehicle (repeated measures ANOVA followed by Dunnett).

https://doi.org/10.1371/journal.pone.0145849.g007

Next, the GPR39 agonists were tested in DIO mouse and in Zucker fatty rat disease models. As shown in Fig 8 for the DIO mouse experiments, none of the agonists showed insulinotropic effects. Moreover, all three compounds yielded significant hyperglycemic effects at their 30 or 100 mg/kg doses. In this study, the 100 mg/kg AZ1395 group was terminated due to severe hyperglycemia and associated morbidity/mortality in some animals. The Zucker fatty rat experiments showed similar trends for the three compounds as shown in S1 Fig.

[Figure omitted. See PDF.]

Fig 8. IPGTT in DIO mice; AZ7914 (A), AZ4237 (B), AZ1395 (C).

Compounds (black triangles: 30 mg/kg, black circles: 100 mg/kg, grey circles: exendin-4, 1 μg/kg) or vehicle (white circles) were IP administered to fasted DIO mice at -30 min. Glucose solution (1.0 g/kg) was IP given at 0 min. Values are mean ± SEM (n = 7). ^#P<0.05, ^##P<0.01, ^###P<0.001 versus vehicle (repeated measures ANOVA followed by student’s t-test).*P<0.05, **P<0.01, ***P<0.001 versus vehicle (repeated measures ANOVA followed by Dunnett).

https://doi.org/10.1371/journal.pone.0145849.g008

PKPD assessment

PK data were generated in order to relate compound unbound exposures in the in vivo studies to unbound in vitro potency parameters. Plasma concentration-time profiles for each of the three compounds in both C57BL/6J and DIO mice are depicted in Fig 9 and Fig 10, respectively. Dose dependent exposures were seen in both models, although not always a linear dependency, and there was a trend of more durable exposures in the DIO mice compared to the lean mice. The average exposure between 0 and 30 minutes in Fig 9 for each compound in lean mice were calculated and compared to in vitro data as shown in Fig 11. AZ7914, AZ4237 and AZ1395 all displayed in vivo exposure versus in vitro potency ratios >10 for each of the screens in the presence of Zn²⁺, suggesting that none of the DMR, IP1/Gα_q or cAMP/Gα_s + Zn²⁺ screens were predictive of improved GSIS in vivo. In the absence of Zn²⁺, the only in vivo exposure versus in vitro potency ratio exceeding 10 was for the DMR assay with AZ1395. Thus, from these data on AZ1395 and the lack of positive in vivo effects, it seems that DMR in vitro potencies in the absence of added Zn²⁺ does not translate to desired in vivo effects.

[Figure omitted. See PDF.]

Fig 9. Plasma concentration–time profile of test compounds in the IPGTT using C57BL/6J mice; AZ7914 (A), AZ4237 (B), AZ1395 (C).

Compounds were IP administered to fasted C57BL/6J mice at -30 min as described in the Fig 7 legend. Data represent the value of pooled samples from 7 animals.

https://doi.org/10.1371/journal.pone.0145849.g009

[Figure omitted. See PDF.]

Fig 10. Plasma concentration–time profile of test compounds in the IPGTT using DIO mice; AZ7914 (A), AZ4237 (B), AZ1395 (C).

Compounds were IP administered to fasted DIO mice at -30 min as described in the Fig 8 legend. Data represent the value of pooled samples from 7 animals.

https://doi.org/10.1371/journal.pone.0145849.g010

[Figure omitted. See PDF.]

Fig 11. In vivo exposures versus in vitro potencies for AZ7914 (A), AZ4237 (B), AZ1395 (C).

C_u,_av (μM) / EC₅₀ (μM) and C_u,_av (μM) / K_D (μM) calculated for different compound doses (30 or 100 mg/kg) IP administered to normal C57BL/6J mice. EC₅₀ and K_D values were from in vitro assays (see Table 1) performed in the absence (w/o) or presence of 5 μM Zn²⁺ (+) and adjusted for protein binding. a) Compound weakly active in in vitro assay: Potency >33 μM, E_max ≥ 8%. b) Compound inactive in in vitro assay: Potency >33 μM, E_max < 2%. For bars labeled with a) and b), EC₅₀ = 33 μM has been used for calculations, resulting in overestimation of C_u,_av / EC₅₀ ratios. This is indicated with open bars. Closed bars indicate that EC₅₀ values have been determined to a defined value. ND, not determined.

https://doi.org/10.1371/journal.pone.0145849.g011

AZ7914 and AZ4237 at unbound concentrations of 8.4 and 7.2 μM, respectively, yielded significant increases in GSIS in INS-1E cells. The average in vivo exposures (C_u,av) of AZ7914 and AZ4237 of 29 and 19 μM, respectively, did not elicit insulinotropic effects in vivo, indicating lack of translation of GSIS in INS-1E cells to GSIS in vivo.

Discussion

The aim of the present study was to evaluate effects of GRP39 agonists on insulin secretion and glucose lowering and hence the potential of GPR39 agonism as a therapy for T2D. Three GPR39 agonists derived from HTS were subjected to extensive in vitro and in vivo profiling and utilized as pharmacological tools for target validation studies. The results show that these Zn²⁺ modulated GPR39 agonists did not improve GSIS neither in normal rodents nor in models of β-cell dysfunction.

The HTS based project work presented here suggests that GPR39 is, in the presence of physiologically relevant levels of Zn²⁺ [19,20], a druggable target, amenable to identification of Zn²⁺ modulated potent and selective agonists with potential to be developed into oral drugs. Each of 20 selected chemical clusters contained potent compounds displaying DMR GPR39 EC₅₀ values < 1 μM with physicochemical properties satisfying the Lipinski rule of five criteria [21] that indicate favorable ADME properties. Also, the three compounds, derived from a limited medicinal chemistry program and selected for in vivo profiling, display a high degree of structural diversity. These findings indicate that GPR39 is permissive to binding a broad range of chemotypes for agonistic modulation. This is further supported by recently published Zn²⁺ dependent agonists with yet different chemotypes [22–24]. The druggability of GPR39 is good news and provides an opportunity to further probe the pharmacology of this receptor.

GPR39 couples to Gα_q, Gα_s and Gα_12/13 pathways. This multiple coupling may be a differentiating advantage for the GPR39 target within the field of diabetes versus GPCRs with a more restricted coupling, e.g. GPR40 (mainly Gα_q/11) [25] and GPR119 (mainly Gα_s) [26]. The in vitro profiling covered Gα_q and Gα_s signaling pathways through the IP₁ and cAMP assays, respectively, and the DMR assay captures the integrated cellular response, including Gα_12/13 signaling [27]. The IP₁ and cAMP data shown in Table 1 clearly indicate higher IP₁/Gα_q than cAMP/Gα_s potencies in the human GPR39 overexpressing cell lines. The corresponding IP₁/Gα_q potencies in native mouse NIT-1 cells were lower, which may be a consequence of increased number of receptors in the overexpressing system compared to the endogenous GPR39 expressing NIT-1 cells, but also species differences may play a role. It is noted that the IP₁/Gα_q efficacy values in the NIT-1 cells differ dramatically between compounds. The reasons are not known, but may in part be due to potential differences in G-protein composition and GPR39 expression levels between NIT-1 and HEK293 cells. We speculate that the efficacy differences may be physiologically relevant, and that the resolution of efficacy is lost in overexpressing systems. Further work is required to understand efficacy of GPR39 agonists in native cell systems and pathway bias of different agonist series.

GPR39 signaling is activated by Zn²⁺ [6,7], which may also constitute a modulator of an as yet unidentified endogenous GPR39 agonist. Zn²⁺ is regarded as both an agonist and an allosteric modulator of GPR39, and GPR39 is commonly referred to as the zinc sensing receptor. The level of Zn²⁺ in plasma is in the 10 μM range [19,20], but the local and temporal Zn²⁺ concentrations may vary significantly. For example, Herschfinkel et al. have suggested a role of GPR39 in neuronal signaling triggered by synaptically released Zn²⁺ [28,29]. Also, with particular relevance for GSIS and the current work, Zn²⁺ is co-released with insulin from islets, and therefore Zn²⁺ modulated agonists may render a particularly potent effect on GPR39 located on the cell surface of insulin secreting cells. This rational is dependent on the assumption that the Zn²⁺ levels by themselves do not saturate GPR39 signaling and its potential effect on GSIS. We therefore regarded the Zn²⁺ modulated agonists identified in the present study as relevant tools to explore the role of GPR39 on GSIS in vivo.

The DMR Schild experiments in Fig 4 revealed dramatic Zn²⁺ modulation of all three compounds, with potency increases from about 1000 to 10000-fold going from 0 to 33 μM Zn²⁺. In summary, the Zn²⁺ PAM effect is impressive, generic to several chemotypes and occurs at physiologically relevant Zn²⁺ concentrations.

Interestingly, BSI data suggest that there are two Zn²⁺ binding sites on GPR39. In addition, all three AZ compounds were able to directly bind Zn²⁺. Thus, the multiple GPR39, Zn²⁺ and compound interactions are complex and extensions of the operational model of allosteric agonism and modulation [15] may be required to describe them adequately.

So far, no Zn²⁺ independent GPR39 agonist has been reported. It is tempting to speculate that Zn²⁺-compound complexes interact at one specific site on GPR39. However, more work is required to determine if this site is separate from or involves the N-terminal His¹⁷ and His¹⁹ residues previously demonstrated as required for GPR39-Zn²⁺ binding [30].

The screening cascade in the GPR39 project was designed to assess and build a platform of evidence regarding in vitro—in vivo correlations with a focus on GSIS. The GSIS in vitro experiments in rat INS-1E cells and mouse islets were performed to evaluate if any of the IP₁/Gα_q, cAMP/Gα_s or DMR potency data would be predictive of GSIS effects. Unfortunately, comparing the INS-1E results in Fig 5 with the data in Table 1, there is no consistent translation between assays. Both AZ7914 and AZ4237 displayed dose dependent GSIS increases in the presence of Zn²⁺ and no effects in the absence of Zn²⁺, in agreement with the screening data shown in Table 1. However, the lack of GSIS effect of AZ1395 was unexpected, considering that AZ1395 was more potent in the IP₁/Gα_q and cAMP/Gα_s assays compared to AZ7914 and AZ4237 in the GPR39 overexpressed cells. The slightly lower IP₁/Gα_q potency but greater efficacy of AZ1395 compared to AZ7914 and AZ4237 in native mouse NIT-1 cells may suggest that the IP₁/Gα_q potencies in the NIT-1 cells may be related to GSIS potencies in the rat INS-1E cells.

The mouse islet GSIS experiments showed no significant effect of any of the three compounds, neither in the presence nor in the absence of Zn²⁺. Thus, there was no correlation between rat INS-1E and mouse islet GSIS data. A recent report on a Zn²⁺ dependent GPR39 agonist with potent Ca²⁺/Gα_q effects showed no effects on GSIS in human islets and in INS-1E cells [22]. The lack of correlations between assays on recombinant cells and assays on cells endogenously expressing GPR39 is a frustrating dilemma, both regarding drug discovery feasibility and regarding building a pharmacological understanding of the target. In light of the precedence for GPR39 playing a role in GSIS [4], the effects on GSIS in INS-1E cells presented here, and a weak trend between DMR and INS-1E data in the presence of Zn²⁺ (data not shown), glucose tolerance tests in vivo were conducted to further explore the role of GPR39 on GSIS.

Three types of in vivo experiments were performed. The first in vivo IPGTT study was performed on healthy lean mice. None of the three AZ compounds showed any significant insulinotropic effects. In the second study, DIO mice were utilized to assess the effect of GPR39 agonism on GSIS in a disease model. As in lean mice, no compound displayed any insulinotropic effects. Surprisingly, all three AZ compounds showed dose dependent hyperglycemic effects. Zucker fatty rats were tested in the third in vivo study, both in order to assess an alternative disease model and to test a second species. The results were similar to those in the DIO mouse study (not shown). The hyperglycemic effects of the GPR39 agonists tested in this study were unexpected in the context of the hypothesis being tested, but it is noted that the role of GPR39 activity in regulating glucose homeostasis has been controversial [12] and the possibility that GPR39 agonism adversely affects insulin sensitivity cannot be discounted. One possibility is that G_s signalling triggered by GPR39 causes glucose release from the liver (similar to glucagon and noradrenaline), and high expression of GPR39 in liver has been confirmed [5]. The role of glucagon in the context of potential GPR39 driven hyperglycemia was not explored in this work since GPR39 is absent in alpha-cells [4]. In summary, our in vivo studies show that none of the tested GPR39 agonists provide any beneficial increased GSIS effects, neither in normal mice nor in rodent models of β-cell dysfunction.

In order to aid interpretation of the in vivo data in the context of GPR39 pharmacology, an analysis of unbound compound exposure in vivo in relation to unbound in vitro potencies was carried out. The ratios of the compounds average unbound in vivo concentrations divided by their unbound in vitro EC₅₀ values presented in Fig 11 are summarized and interpreted as follows: For the mouse DMR and human cAMP/Gα_s data in the GPR39 overexpressing cells in the presence of Zn²⁺, the ratios range from 4.7 to 260 and from 0.81 to 86, respectively, i.e. ample compound coverage in vivo was achieved to conclude that none of these in vitro potency parameters translate to a positive GSIS effect in vivo. The same interpretation applies to the IP₁/Gα_q data using NIT-1 cells (endogenously expressing GPR39), since the corresponding ratio range was similar (0.30 to 78). The three-point concentration response INS-1E GSIS data allows only for a rough comparison to the in vivo exposure data. The in vivo exposures of AZ7914 and AZ4237 were 29 and 19 μM, respectively, to be compared with the highest unbound concentrations of 8.4 and 7.2 μM in the INS-1E experiments. Thus, the in vivo exposures achieved for these two compounds indicate that the INS-1E effects were not predictive of an in vivo effect. All together, the in vivo exposure versus in vitro potency analysis suggest that none of the DMR, IP₁/Gα_q or cAMP/Gα_s in vitro potency data generated in the presence of Zn²⁺ are predictive of positive GSIS effects in vivo. Future identification of potent and selective GPR39 agonists in the absence of Zn²⁺ would be valuable to further explore the therapeutic potential of GPR39.

Summary and Conclusion

An HTS based GPR39 agonist lead generation project readily identified 20 Zn²⁺ modulated clusters displaying reasonable physicochemical properties, supporting GPR39 as a druggable target for this mode of action. Following a limited medicinal chemistry program, three structurally diverse compounds were selected as tools to explore the utility of GPR39 agonism on improved GSIS in vivo. The lack of positive in vivo effects limited the PKPD investigation to an analysis comparing in vivo exposure data to in vitro potency data. The conclusion from this analysis is that high in vivo exposures in relation to the DMR, IP₁/Gα_q and cAMP/Gα_s potencies in the presence of physiologically relevant concentrations of Zn²⁺ were not sufficient to yield improved GSIS, neither in normal nor pre-clinical models of β-cell dysfunction. Thus, Zn²⁺ modulated GPR39 agonism does not support this approach to glucose lowering in T2D.

Supporting Information

[Figure omitted. See PDF.]

S1 Fig. IPGTT in Zucker fatty rat.

https://doi.org/10.1371/journal.pone.0145849.s001

(TIF)

S1 File. Chemistry synthesis and experimental details.

https://doi.org/10.1371/journal.pone.0145849.s002

(PDF)

Acknowledgments

We thank Terese Andersson, Krystle Isaksson da Silva and Erik Olandersson for preparation of the compounds used in the present study. We also thank Tamotsu Shimazaki, Kumiko Yoshida, Masato Takeuchi and Shuichi Harada for technical assistance in the in vivo tests and Takashi Tozawa, Masahiro Eda, Naoki Suto, Kanami Sugimoto and Satoko Kiuchi for discussion on the interpretation of the data.

Author Contributions

Conceived and designed the experiments: OF NL SY TT TO AM CWH DH HF YY KS AJ SL JB RJI DB SG LB CP AT. Performed the experiments: NL SY TT TO DH HF YY KS SL JB RJI DB SG CP. Analyzed the data: OF NL SY TT TO AM CWH DH HF YY KS AJ SL JB RJI DB SG LB CP AT. Contributed reagents/materials/analysis tools: JB RJI DB CP. Wrote the paper: OF NL SY TT TO AM CWH HF AJ RJI SG.

Citation: Fjellström O, Larsson N, Yasuda S-i, Tsuchida T, Oguma T, Marley A, et al. (2015) Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents. PLoS ONE 10(12): e0145849. https://doi.org/10.1371/journal.pone.0145849

References

1. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes. 2005;54: S108–S113. pmid:16306327

2. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discovery. 2009;8: 369–385.

3. Popovics P, Stewart AJ. GPR39: a Zn2+-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci. 2011;68: 85–95. pmid:20812023

4. Holst B, Egerod KL, Jin C, Petersen PS, Oestergaard MV, Hald J, et al. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology. 2009;150: 2577–2585. pmid:19213833

5. Moechars D, Depoortere I, Moreaux B, De Smet B, Goris I, Hoskens L, et al. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology. 2006;131: 1131–1141. pmid:17030183

6. Yasuda S, Miyazaki T, Munechika K, Yamashita M, Ikeda Y, Kamizono A. Isolation of Zn2+ as an Endogenous Agonist of GPR39 from Fetal Bovine Serum. J Recept Signal Transduction. 2007;27: 235–246.

7. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach L, et al. GPR39 signaling is stimulated by zinc ions but not by Obestatin. Endocrinology. 2007;148: 13–20. pmid:16959833

8. Tremblay F, Richard AT, Will S, Syed J, Stedman N, Perreault M, et al. Disruption of G protein-coupled receptor 39 impairs insulin secretion in vivo. Endocrinology. 2009;150: 2586–2595. pmid:19213841

9. Egerod KL, Jin C, Petersen PS, Wierup N, Sundler F, Holst B, et al. Beta-Cell specific overexpression of GPR39 protects against streptozotocin-induced hyperglycemia. Int J Endocrinol. 2011: 401258, 8. pmid:22164158

10. Verhulst PJ, Lintermans A, Janssen S, Loeckxt D, Himmelreicht U, Buyse J, et al. GPR39, a receptor of the ghrelin receptor family, plays a role in the regulation of glucose homeostasis in a mouse model of early onset diet-induced obesity. J Neuroendocrinol. 2011;23: 490–500. pmid:21470317

11. Petersen PS, Jin C, Madsen AN, Rasmussen M, Kuhre R, Egerod KL, et al. Deficiency of the GPR39 receptor is associated with obesity and altered adipocyte metabolism. Faseb J. 2011;25: 3803–3814. pmid:21784784

12. Depoortere I. GI functions of GPR39: novel biology. Curr Opin Pharmacol. 2012;12: 647–652. pmid:22884904

13. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW. Common Structural Basis for Constitutive Activity of the Ghrelin Receptor Family. J Biol Chem. 2004;279: 53806–53817. pmid:15383539

14. Bornhop DJ, Latham JC, Kussrow A, Markov DA, Jones RD, Sorensen HS. Free-Solution, Label-Free Molecular Interactions Studied by Back-Scattering Interferometry. Science. 2007;317: 1732–1736. pmid:17885132

15. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci. 2007;28: 382–389. pmid:17629965

16. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes. 2007;56: 1694–1702. pmid:17360975

17. Fang Y. Label-free biosensors for cell biology. Int J Electrochem. 2011:

18. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metab, Clin Exp. 2001;50: 583–589.

19. Caroli S, Alimonti A, Coni E, Petrucci F, Senofonte O, Violante N. The assessment of reference values for elements in human biological tissues and fluids: a systematic review. Crit Rev Anal Chem. 1994;24: 363–398.

20. Lu J, Stewart AJ, Sleep D, Sadler PJ, Pinheiro TJT, Blindauer CA. A Molecular Mechanism for Modulating Plasma Zn Speciation by Fatty Acids. J Am Chem Soc. 2012;134: 1454–1457. pmid:22239162

21. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23: 3–25.

22. Boehm M, Hepworth D, Loria PM, Norquay LD, Filipski KJ, Chin JE, et al. Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. ACS Med Chem Lett. 2013;4: 1079–1084. pmid:24900608

23. Bassilana F, Carlson A, Da Silva JA, Grosshans B, Vidal S, Beck V, et al. Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. Nat Chem Biol. 2014;10: 343–349. pmid:24633354

24. Peukert S, Hughes R, Nunez J, He G, Yan Z, Jain R, et al. Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. ACS Med Chem Lett. 2014;5: 1114–1118. pmid:25313322

25. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?. Trends Endocrinol Metab. 2013;24: 398–407. pmid:23631851

26. Ohishi T, Yoshida S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Invest Drugs. 2012;21: 321–328.

27. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol. 2010;28: 943–949. pmid:20711173

28. Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, et al. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. J Neurosci. 2009;29: 2890–2901. pmid:19261885

29. Chorin E, Vinograd O, Fleidervish I, Gilad D, Herrmann S, Sekler I, et al. Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor. J Neurosci. 2011;31: 12916–12926. pmid:21900570

30. Storjohann L, Holst B, Schwartz TW. Molecular mechanism of Zn2+ agonism in the extracellular domain of GPR39. FEBS Lett. 2008;582: 2583–2588. pmid:18588883